RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • 5,0 (3)
  • МЕДИЦИНА
RhAPPcast

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. -1 Ч

    FAQ: How Does Real-World Evidence Differ From Randomized Controlled Trials

    Join Jennifer Mylod, a nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, as she explores the differences between real-world evidence and randomized controlled trials (RCTs) in assessing medical treatments.

    3 мин.

  2. -5 ДН.

    How long has it been since the last ACR LN guideline updates and why is this significant?

    In this educational series, Amanda Mixon, PA-C, President of RhAPP, introduces the latest Lupus Nephritis education based on the updated ACR guidelines. Since the last guidelines in 2012, new therapies like belimumab and voclosporin have revolutionized treatment approaches. The shift from traditional high-dose steroid induction to targeted immune pathway therapies aims to preserve kidney function while reducing medication toxicity. The new guidelines emphasize lower-dose glucocorticoid regimens, triple therapy for Class III & IV Lupus Nephritis, and frequent proteinuria monitoring to optimize patient outcomes. Stay updated with FAQs, podcasts, and medication reviews on the RhAPP website and RhAPP ACE 2.0 Mobile App.

    3 мин.

  3. 28 ЯНВ.

    Effectiveness of methotrexate and leflunomide as corticoid – sparing drugs in patients with polymyalgia rheumatica

    Danielle Gatti Palumbo, PharmD, presents a Journal Club discussion on a study evaluating the effectiveness of Methotrexate and Leflunomide as steroid-sparing drugs in patients with Polymyalgia Rheumatica (PMR). The study found that Leflunomide was more effective than Methotrexate in achieving steroid withdrawal and remission, with patients on Leflunomide achieving steroid discontinuation more quickly. Despite both treatments showing similar tolerability, Leflunomide demonstrated superior outcomes in terms of remission and faster steroid withdrawal. The study highlights Leflunomide as a promising option for PMR patients, though further research is needed to confirm these findings.

    4 мин.
  4. RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA

    22 ЯНВ.

    RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA

    Host Amanda Mixon, President of RhAPP, is joined by Audrey Gibson, a Physician Assistant and fellow RhAPP member. They explore the clinical utility of guselkumab for treating axial psoriatic arthritis, a topic gaining significant interest in the rheumatology community.Audrey shares insights from key clinical trials and offers practical advice on using IL-23 inhibitors in clinical practice. Whether you’re an experienced practitioner or new to the field, this discussion will enhance your unders...

    21 мин.
  5. Journal Club Review Video Module

    15 ЯНВ.

    Journal Club Review Video Module

    Amber Hudgins, PharmD, CPP, discusses the efficacy and safety of ixekizumab in biologic-naive patients with psoriatic arthritis, comparing it to adalimumab with and without methotrexate. She dives into the results of the SPIRIT-H2H study, highlighting key findings on joint and skin improvements at 52 weeks. Amber explains how ixekizumab delivers consistent efficacy regardless of methotrexate use, offering valuable insights for evidence-based treatment decisions in PsA management

    6 мин.
  6. FAQ: How do you interpret radiographic progression using modified-vdHS or mTSS

    8 ЯНВ.

    FAQ: How do you interpret radiographic progression using modified-vdHS or mTSS

    Join Kyle George as he explains the use of radiographic scoring systems in assessing structural damage and progression in psoriatic arthritis (PsA). In this informative video, Kyle discusses the modified Van der Heijde Sharp score (mVHS) and the modified Total Sharp score (mTSS), both of which utilize radiographic images to document changes in the hands, wrists, and feet.

    2 мин.
  7. Med. Review Video Module: What is the efficacy of ixekizumab across the GRAPPA & EULAR domains?

    16.12.2024

    Med. Review Video Module: What is the efficacy of ixekizumab across the GRAPPA & EULAR domains?

    Join Jessica Farrell, PharmD, a clinical pharmacist and board member of RhAPP, as she breaks down the efficacy of ixekizumab across the GRAPPA domains. In this video, she covers the impact of ixekizumab on peripheral arthritis, axial disease, enthesitis, dactylitis, skin, and nail psoriasis, based on the latest clinical trial data. Learn how this treatment can significantly improve various symptoms in patients with psoriatic arthritis.

    7 мин.
  8. Medication Review Video Module: What is the safety profile of guselkumab in PsO and PsA?

    11.12.2024

    Medication Review Video Module: What is the safety profile of guselkumab in PsO and PsA?

    Join Cassie Dolecki, a clinical pharmacy specialist in Rheumatology at Allegheny Health Network in Pittsburgh, Pennsylvania, as she discusses the safety profile of guselkumab in treating psoriatic arthritis and psoriasis. Cassie highlights findings from the DISCOVER-2 trial, a phase three study that assessed the efficacy and safety of guselkumab compared to placebo in biologic-naive patients with active psoriatic disease over two years.

    2 мин.
См. все (64)

Оценки и отзывы

5
из 5
Оценок: 3

Об этом подкасте

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

Информация

  • Автор
    Rheumatology Advanced Practice Providers (RhAPP)
  • Годы выхода
    2023 - 2025
  • Выпуски
    64
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2025 RhAPPcast
  • Сайт подкаста
    RhAPPcast

Вам может также понравиться

Чтобы прослушивать выпуски с ненормативным контентом, войдите в систему.

Следите за новостями подкаста

Войдите в систему или зарегистрируйтесь, чтобы следить за подкастами, сохранять выпуски и получать последние обновления.
Выберите страну или регион

Африка, Ближний Восток и Индия

Азиатско-Тихоокеанский регион

Европа

Латинская Америка и страны Карибского бассейна

США и Канада